Determination of Cytotoxicity, Biological Effects and Anti-Human Breast Cancer Properties of Bilobol

The current research used Bilobol to determine the cytotoxicity and anti-human breast cancer properties with molecular docking studies. The properties of Bilobol against breast cell lines i.e. Hs578T, MDA-MB-231, SkBr3, BT-549, MCF-7, AU565, 600MPE, and Evsa-T were evaluated in the in vitro condition. The IC50 of the Bilobol was 258, 236, 161, 265, 250, 183, 256, and 233 µM against MDA-MB-231, Hs578T, SkBr3, BT-549, MCF-7, AU565, Evsa-T, and 600MPE, respectively. The molecular modeling evaluation analyzed the chemical effects of bilobol against alpha-amylase and alpha-glucosidase. The anti-cancer activities of the molecules were examined against MDA-MB-231, Hs578T, SkBr3, BT-549, MCF-7, AU565, Evsa-T, and 600MPE cell lines. Following completion of clinical trial research, the novel compound may find application in human supplementation against breast cancer. Bilobol's IC50 values for the enzymes α-amylase and α-glucosidase were found to be 45.13 and 11.82 µM, respectively. In the aforementioned cell lines, bilobol's chemical interactions with a few expressed surface receptor proteins (EGFR, CD47, androgen receptor, folate receptor, HER2, CD44, progesterone receptor, and estrogen receptor) were determined using molecular modeling calculations. The outcomes displayed the likely atomic-level interactions and their properties. According to the docking scores, this chemical has a high affinity for certain proteins and enzymes. Additionally, this substance made strong contact with the receptors and enzymes. As a result, both enzymes and cancer cells may be inhibited by this chemical molecule.